Karen Liby, PhD

Adjunct Professor

libykare@msu.edu

Research

Cancer

Sections

PHM 802 Cellular, Molecular and Integrated Systems Pharmacology (in-person) - Spring

Funding

Chemoprevention of experimental estrogen receptor negative breast cancer, The Breast Cancer Research Foundation Inc. (2023-10-01—2024-09-30)
Chemoprevention of experimental estrogen receptor negative breast cancer, The Breast Cancer Research Foundation Inc. (2024-10-01—2025-09-30)
Nrf2, immune cells and lung cancer, National Cancer Institute (2019-04-01—2024-03-31)
Nanoformulations and Sustained Delivery of PARP Inhibitors for Breast Cancer, Congressionally Directed Medical Research Programs (2016-09-30—2021-09-29)
16K Prolactin as an Angiogenic Inhibitor in Breast Cancer, Congressionally Directed Medical Research Programs (1997-10-01—1998-09-01)
Chemoprevention of experimental estrogen receptor negative breast cancer, The Breast Cancer Research Foundation Inc. (2022-10-01—2023-09-30)

Works

The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice. International Journal of Molecular Sciences (2024-09-16)
The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer. Antioxidants (2024-05-21)
KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype. International Journal of Molecular Sciences (2024-03-20)
KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype. International Journal of Molecular Sciences (2024)
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis. Molecules and Cells (2023-03-31)
Ocular injury progression and cornea histopathology from chloropicrin vapor exposure: Relevant clinical biomarkers in mice. Experimental eye research (2023)
The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice. International journal of molecular sciences (2023)
The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner. Antioxidants (Basel, Switzerland) (2023)
Exploring structural effects in a new class of NRF2 inhibitors. RSC medicinal chemistry (2022)
T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages. Frontiers in Immunology (2022)
The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports (2022)
The Rexinoid V-125 Reduces Tumor Growth in Preclinical Models of Breast and Lung Cancer. (2021)
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. Journal of cancer prevention (2021)
A novel Nrf2 pathway inhibitor sensitizes keap1-mutant lung cancer cells to chemotherapy. Molecular Cancer Therapeutics (2021)
Potential therapeutic uses of rexinoids. Advances in Pharmacology (2021)
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. Scientific Reports (2021)
The bromodomain inhibitor, incb057643, targets both cancer cells and the tumor microenvironment in two preclinical models of pancreatic cancer. Cancers (2021)
The rxr agonist msu42011 is effective for the treatment of preclinical her2+ breast cancer and kras-driven lung cancer. Cancers (2021)
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. Scientific Reports (2020)
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports (2020)
Profiling changes in metabolism and the immune microenvironment in lung tumorigenesis. Annals of translational medicine (2019)
A nano-liposome formulation of the PARP inhibitor talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics (2019)
Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay. Scientific Reports (2019)
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. npj Breast Cancer (2019)
Testing novel pyrimidinyl rexinoids: A new paradigm for evaluating rexinoids for cancer prevention. Cancer Prevention Research (2019)
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras ^G12D ; Pdx1-Cre (KC) mice. Scientific Reports (2019)
A BET bromodomain inhibitor suppresses adiposity-associated malignant transformation. Cancer Prevention Research (2018)
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. Cancer Prevention Research (2018)
Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. Scientific Reports (2018)
Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation. Biochemical Pharmacology (2018)
Identification of an unfavorable immune signature in advanced lung tumors from Nrf2-deficient mice. Antioxidants and Redox Signaling (2018)
Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer. Current Protocols in Pharmacology (2018)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. (2017)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters (2017)
Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H2O2 in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing. (2017)
Nrf2-Dependent and -Independent Effects of tert-Butylhydroquinone, CDDO-Im, and H₂O₂ in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing. Journal of Pharmacology and Experimental Therapeutics (2017)
Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids. Organic and Biomolecular Chemistry (2017)
NRF2 as an Emerging Therapeutic Target. (2017)
NRF2 as an emerging therapeutic target. Oxidative Medicine and Cellular Longevity (2017)
Rexinoids for prevention and treatment of cancer: Opportunities and challenges. Current Topics in Medicinal Chemistry (2017)
Sustained release Talazoparib implants for localized treatment of Brca1-deficient breast cancer. Theranostics (2017)
Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria. Malaria Journal (2017)
The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. (2016)
Rexinoids for prevention and treatment of cancer: opportunities and challenges. (2016)
The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice. (2016)
The rexinoids LG100268 and LG101506 inhibit inflammation and suppress lung carcinogenesis in A/J mice. Cancer Prevention Research (2016)
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. (2016)
CDDO-Me redirects activation of breast tumor associated macrophages. PLoS ONE (2016)
The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. Carcinogenesis (2016)
Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. (2015)
Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacological Research (2015)
Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. (2015)
Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis (2015)
Erratum to Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells (Cell Cycle, 14, 4 (648-655), 10.4161/15384101.2014.994966). Cell Cycle (2015)
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. (2015)
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle (2015)
The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. (2014)
The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. Inflammopharmacology (2014)
PARP inhibitors for chemoprevention--reply. (2014)
PARP inhibitors for chemoprevention - Reply. Cancer Prevention Research (2014)
An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): analogues, biological activities, and comparison with oleanolic acid derivatives. (2014)
An efficient synthesis of methyl 2-cyano-3,12-dioxoursol-1,9-dien-28-oate (CDDU-methyl ester): Analogues, biological activities, and comparison with oleanolic acid derivatives. Organic and Biomolecular Chemistry (2014)
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. (2014)
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prevention Research (2014)
Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). (2014)
Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). Bioorganic and Medicinal Chemistry Letters (2014)
Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. (2014)
Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with carboplatin and paclitaxel in experimental lung cancer. Dose-Response (2014)
A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. (2014)
A synthetic triterpenoid cddo-im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS ONE (2014)
Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. (2013)
Oral administration of a Gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prevention Research (2013)
Is lycopene an effective agent for preventing prostate cancer?. (2013)
Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. (2013)
Targeting nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of parkinson's disease. Antioxidants and Redox Signaling (2013)
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. (2013)
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis (2013)
ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. (2013)
Δnp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Research (2013)
A mini-review of chemoprevention of cancer - past, present, and future. Progress in Chemistry (2013)
Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. (2012)
Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacological Reviews (2012)
NRF2 and cancer: the good, the bad and the importance of context. (2012)
NRF2 and cancer: The Good, the bad and the importance of context. Nature Reviews Cancer (2012)
The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. (2012)
The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prevention Research (2012)
CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. (2012)
CDDO-methyl ester delays breast cancer development in Brca1-mutated mice. Cancer Prevention Research (2012)
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. (2011)
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine (2011)
CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. (2011)
CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prevention Research (2011)
New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. (2011)
New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. Journal of Natural Products (2011)
The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. (2011)
The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clinical and Experimental Metastasis (2011)
Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. (2011)
Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS ONE (2011)
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. (2011)
Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Scientific Reports (2011)
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. (2010)
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prevention Research (2010)
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. (2010)
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine (2010)
2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. (2010)
2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic and Medicinal Chemistry Letters (2010)
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. (2010)
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research (2010)
Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. (2009)
Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prevention Research (2009)
Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. (2009)
Synthetic triterpenoids attenuate cytotoxic retinal injury: Cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Investigative Ophthalmology and Visual Science (2009)
The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. (2009)
The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. American Journal of Respiratory and Critical Care Medicine (2009)
Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. (2009)
Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide. European Journal of Pharmacology (2009)
Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. (2009)
Genetic versus chemoprotective activation of Nrf2 signaling: Overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis (2009)
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. (2009)
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE (2009)
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. (2009)
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry (2009)
Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. (2009)
Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America (2009)
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease: (Journal of Neurochemistry (2009) 109 (502-512)). Journal of Neurochemistry (2009)
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. (2008)
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Research (2008)
Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. (2008)
Genetic or pharmacologic amplification of Nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicological Sciences (2008)
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. (2008)
Prevention and treatment of experimental estrogen receptor- negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clinical Cancer Research (2008)
Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. (2008)
Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biology and Therapy (2008)
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. (2008)
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics (2008)
A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. (2008)
A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. Biochemical and Biophysical Research Communications (2008)
Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. (2007)
Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxidants and Redox Signaling (2007)
A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. (2007)
A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clinical Cancer Research (2007)
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. (2007)
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities. Molecular Cancer Therapeutics (2007)
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. (2007)
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Reviews Cancer (2007)
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents. (2007)
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: Highly potent anti-inflammatory and cytoprotective agents. Journal of Medicinal Chemistry (2007)
JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells. (2007)
JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells. Journal of Biological Chemistry (2007)
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. (2007)
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Research (2007)
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. (2007)
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Molecular Cancer Therapeutics (2007)
Platforms and networks in triterpenoid pharmacology. Drug Development Research (2007)
Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. (2006)
Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorganic and Medicinal Chemistry Letters (2006)
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. (2006)
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochemical and Biophysical Research Communications (2006)
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. (2006)
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β. Molecular Cancer Therapeutics (2006)
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. (2006)
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clinical Cancer Research (2006)
Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. (2006)
Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Letters (2006)
The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. (2006)
The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. (2006)
The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Molecular Cancer Therapeutics (2006)
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. (2006)
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole. Cancer Research (2006)
Cancer chemoprevention: scientific promise, clinical uncertainty. (2005)
Cancer chemoprevention: Scientific promise, clinical uncertainty. Nature Clinical Practice Oncology (2005)
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. (2005)
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Research (2005)
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. (2005)
Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America (2005)
Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. (2004)
Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. Journal of Medicinal Chemistry (2004)
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. (2004)
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor 13-dependent apoptosis in breast cancer. Cancer Research (2004)
Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. (2003)
Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Research and Treatment (2003)
Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. (2003)
Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. Cancer Biology and Therapy (2003)
Prolactin as an autocrine/paracrine growth factor in human cancer. (2002)
Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism (2002)
Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase. (2001)
Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase. Mitochondrial DNA (2001)
Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. (1999)
Proteolysis of human prolactin: Resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology (1999)
Prolactin as a local growth factor in breast cancer. ()

Employment

Professor, Indiana University (2023-09-01)